NVO241227C120000
- 0.01
- -0.01-50.00%
Novo-Nordisk A/S Newsroom
BMO Capital has lowered the Target Price for Novo-Nordisk A/S to $105.
Major Bank Rating | TD Cowen: Downgraded Novo-Nordisk A/S Target Price to $105, maintaining "Buy" rating.
BMO Capital Maintains Outperform on Novo Nordisk, Lowers Price Target to $105
Novo Nordisk Analyst Ratings
TD Cowen Maintains Novo-Nordisk A/S(NVO.US) With Buy Rating, Cuts Target Price to $105
BMO Capital Maintains Novo-Nordisk A/S(NVO.US) With Buy Rating, Cuts Target Price to $105
Jefferies Maintains Novo-Nordisk A/S(NVO.US) With Sell Rating, Cuts Target Price to $81.5
CFRA Initiates Novo-Nordisk A/S(NVO.US) With Hold Rating, Announces Target Price $122
TD Cowen Maintains Novo-Nordisk A/S(NVO.US) With Buy Rating, Maintains Target Price $155
The Trader: Eli Lilly and 2 More Drug Stocks to Buy After RFK-Inspired Drop -- Barron's
BMO Capital Maintains Novo-Nordisk A/S(NVO.US) With Buy Rating, Maintains Target Price $156
Eli Lilly and 2 More Drug Stocks to Buy After RFK-Inspired Drop -- Barrons.com
BofA Securities Maintains Novo-Nordisk A/S(NVO.US) With Buy Rating
TD Cowen Maintains Novo-Nordisk A/S(NVO.US) With Buy Rating, Announces Target Price $155
Novo Nordisk Analyst Ratings
TD Cowen Maintains Novo-Nordisk A/S(NVO.US) With Buy Rating
Cantor Fitzgerald Maintains Novo-Nordisk A/S(NVO.US) With Buy Rating, Maintains Target Price $160
Erste Group Initiates Novo-Nordisk A/S(NVO.US) With Hold Rating
Amylyx Upgraded to Buy by BofA on Hypoglycemia Drug Potential
BMO Capital Maintains Novo-Nordisk A/S(NVO.US) With Buy Rating, Cuts Target Price to $156